EU Approves AbbVie's Rinvoq for Severe Alopecia Areata and Vitiligo

SentiSense · Published · Updated

AbbVie announced European Union approval for Rinvoq to treat severe alopecia areata and non-segmental vitiligo.

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis